Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Operating Leases (2019 - 2023)

Historic Operating Leases for Spyre Therapeutics (SYRE) over the last 5 years, with Q1 2023 value amounting to $3.8 million.

  • Spyre Therapeutics' Operating Leases fell 1441.68% to $3.8 million in Q1 2023 from the same period last year, while for Mar 2023 it was $3.8 million, marking a year-over-year decrease of 1441.68%. This contributed to the annual value of $4.0 million for FY2022, which is 1310.76% down from last year.
  • Per Spyre Therapeutics' latest filing, its Operating Leases stood at $3.8 million for Q1 2023, which was down 1441.68% from $4.0 million recorded in Q4 2022.
  • Spyre Therapeutics' Operating Leases' 5-year high stood at $5.1 million during Q4 2020, with a 5-year trough of $372000.0 in Q1 2019.
  • Moreover, its 5-year median value for Operating Leases was $4.7 million (2019), whereas its average is $4.4 million.
  • As far as peak fluctuations go, Spyre Therapeutics' Operating Leases soared by 119435.48% in 2020, and later plummeted by 1441.68% in 2023.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Operating Leases stood at $4.7 million in 2019, then grew by 8.85% to $5.1 million in 2020, then decreased by 10.16% to $4.6 million in 2021, then dropped by 13.11% to $4.0 million in 2022, then decreased by 4.52% to $3.8 million in 2023.
  • Its Operating Leases stands at $3.8 million for Q1 2023, versus $4.0 million for Q4 2022 and $4.2 million for Q3 2022.